Drug Profile
GR 1405
Alternative Names: GR-1405Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Genrix (Shanghai) Biopharmaceuticals
- Developer 307th Hospital of Chinese Peoples Liberation Army; Genrix (Shanghai) Biopharmaceuticals
- Class Antineoplastics; Monoclonal antibodies; Recombinant proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lymphoma; Solid tumours
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Lymphoma(In the elderly, Second-line therapy or greater, In adults) in China (IV, Injection)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in China (IV, Injection)
- 23 Jun 2020 Genrix (Shanghai) Biopharmaceuticals plans a phase I/II trial for Breast cancer (In adults, In the elderly, Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (ChiCTR2000029189)